GAMMA Investing’s Biodexa Pharmaceuticals BDRX Stock Holding History

GAMMA Investing’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-150	Closed	-$3.5K	–	4334
2026 Q2	$3.5K	Sell	150 -195	-57%	-$5.26K	﹤0.01%	3610
2026 Q1	$8.52K	Buy	345 +301	+684%	+$16.9K	﹤0.01%	3155
2025 Q4	$4.03K	Buy	44 +10	+29%	+$2.28K	﹤0.01%	3372
2025 Q3	$8.99K	Buy	34 +4	+13%	+$1.15K	﹤0.01%	2933
2025 Q2	$10.3K	Buy	30 +26	+650%	+$13.3K	﹤0.01%	2784
2025 Q1	$1.88K	Buy	+4	New	+$5.6K	﹤0.01%	3430
2024 Q4	–	Hold	0	–	-$81	–	3784
2024 Q3	–	Hold	0	–	–	–	3561
2024 Q2	–	Sell	-1	Closed	-$10.5K	–	2693
2024 Q1	$18K	Buy	+1	New	+$15.8K	﹤0.01%	1722
2023 Q4	–	Hold	0	–	–	–	2635

Other funds holding BDRX

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

GAMMA Investing's BDRX Position: Q3 2026 in Review

GAMMA Investing sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2026, closing a stake of 150 shares — an estimated $3.5K sold.

GAMMA Investing first reported a position in BDRX in Q1 2024 and held it in 7 quarters. The position peaked at $18K in Q1 2024. 3 funds tracked by Wall St. Rank hold BDRX as of Q3 2026.

GAMMA Investing reported no remaining Biodexa Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
GAMMA Investing sold 150 Biodexa Pharmaceuticals shares in Q3 2026, an estimated $3.5K.
GAMMA Investing first reported a position in Biodexa Pharmaceuticals in Q1 2024 and held it in 7 quarters.
GAMMA Investing's Biodexa Pharmaceuticals position peaked at $18K in Q1 2024.
3 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.